Abingdon Health PLC
Company Profile
Business description
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
Contact
York Biotech Campus
Sand Hutton
YorkYO41 1LZ
GBRT: +44 1904406050
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 June 2026
Employees
129
Stocks News & Analysis
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
stocks
World’s largest miner overvalued after solid quarter
stocks
Hidden value in an expensive ASX
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,005.30 | 46.10 | -0.51% |
| CAC 40 | 8,156.43 | 79.28 | -0.96% |
| DAX 40 | 24,194.90 | 75.97 | -0.31% |
| Dow JONES (US) | 49,490.03 | 340.65 | 0.69% |
| FTSE 100 | 10,476.46 | 21.63 | -0.21% |
| HKSE | 25,863.22 | 300.02 | -1.15% |
| NASDAQ | 24,657.57 | 397.60 | 1.64% |
| Nikkei 225 | 58,694.86 | 891.00 | -1.50% |
| NZX 50 Index | 12,900.92 | 44.68 | -0.35% |
| S&P 500 | 7,137.90 | 73.89 | 1.05% |
| S&P/ASX 200 | 8,772.00 | 47.50 | -0.54% |
| SSE Composite Index | 4,073.71 | 32.54 | -0.79% |